Matrix Partners invests in MSME lender Five Star Business Credits

Matrix Partners India has led the first institutional round of funding in Five Star Business Credits (Five Star), a leading small business finance company that provides secured loans to micro and small enterprise customers (MSME). Five Star with its proprietary secured lending model has catered to more than 5,000 MSME customers over the last 5 years.

India has 29.8 million MSMEs and a further 30 million MSMEs in the unorganised sector. Formal banking and financial channels find it challenging to address the needs of MSME customers primarily due to the challenges in assessing credit quality of such customers. 

According to D Lakshmipathy, Managing Director, Five Star, MSME lending is a significantly underserved market in India not addressed by formal financial channels. "We have built a unique credit assessment model for deserving customers that run small but healthy businesses and all our loans are collateral backed. This round of funding from Matrix should help us further expand our branch footprint and enhance our funding base for long term expansion,” said Lakshmipathy.

Operators of small shop owners (provision stores, small restaurants, textile stores, bakery outlets, medical stores etc), small and medium machine shop operators, self employed people etc are key customers of Five Star that also provides loans for the purpose of home improvement to MSME customers. The company is present across 30 branches in Tamil Nadu and is planning to further expand its footprint across different states in India.

“Five Star has a highly differentiated, secured and sustainable lending model to address the large, underserved MSME financing opportunity. Financial services is an important focus area for the firm. We share Lakshmipathy’s vision and passion for this sector and look forward to being his partners in this journey,” said Rishi Navani, Managing Director, Matrix India.

A private investment firm Matrix Partners has Rs 3,000 crore under management and invests in companies targeting the Indian consumer market at the seed, early and early growth stages. It has a global network of funds investing in the US, China and India with $3 billion under management.

So far, Matrix Partners has invested in several market leading companies including Muthoot Finance (gold loan NBFC), TreeHouse Education (preschools), Cloudnine (maternity and infant care chain), Mswipe (mobile POS), Verse/NewsHunt (vernacular mobile platform) and Quikr (online classifieds).

Why should one invest in a residential property in Mumbai?

At the age of 23 when she had just started working, Shirin Gadbade acquired a ready-to-move, two-bedroom, hall, kitchen (BHK) flat in Pancham Apartments at Link Road, Borivali (West) for an all inclusive cost of around Rs 22 lakh.

Having fully paid back the bank loan taken to fund this acquisition in 2010, she decided to invest around Rs 80 lakh in another two-and-half BHK apartment at the Rustomjee Urbania development on the Eastern Express Highway in Thane (suburban Mumbai) in 2011.

“My mother coaxed me into buying the first flat. I figured investing in property was significantly rewarding when valuation of my apartment increased significantly by the time I'd paid off the home loan. Motivated, I decided on investing in another one for investment purpose and am hoping to replicate the success in the years to come,” she said.

A perfect example of creating wealth through investing in real estate, Shirin took possession of the second residential apartment sometime in 2012. While a large a large part of the total unrealised gains of around Rs 1 crore (majority from the first apartment bought 8-9 years ago) Shirin's real estate portfolio (of two apartments) is currently worth an estimated Rs 2.5 crore odd – all this at the age of 33.

Shirin is among the thousands of other like-minded people who took the plunge investing in real estate at various stages in the last decade or so and are reaping the benefits of this timely decision that helped create wealth.

Elaborating on the approach, Om Ahuja, chief executive officer – residential services, Jones Lang LaSalle India, said it is definitely possible to create wealth through real estate investment as long as one keeps the fundamentals in mind. “Effective investment in residential property requires a location to meet certain parameters. Fundamentally, the area should have good social infrastructure, availability of adequate public transport and sufficient economic activity to sustain development and growth. In order to mitigate most of the investment risk, one should restrict one’s residential property investment to Tier 1 and select Tier 2 cities.

“The investor should keep an eye on the market and sell the residential property at the right time in order to multiply wealth. If all the above precautions have been taken, the property should have appreciated at a consistent rate of 15% per annum for three years,” sid Ahuja adding that it is important to remember that one can almost never sell at the peak, just as it is impossible to always catch the lowest price.

Going by prices compiled by real estate rating and research firm, Liases Foras, different pockets in the Mumbai Metropolitan Region (MMR) and extended suburbs delivered a compound annual growth rate (CAGR) of 20% or more for investments made in 2005. Simply put people who bought real estate assets have seen their money multiply anywhere between 3.7 to 4.9 times depending on the market they invested then.

Lets now look at how prices have behaved in the years between 2005 and 2013. The Liases Foras data for the said duration shows, on an average, real estate prices in the island city rose from Rs 6,637 per square foot (psf) in January 2005 to Rs 30,344 psf in December 2013. In the central and western suburbs prices increased from Rs 3,005 psf and Rs 3,290 psf to Rs 12,418 psf and Rs 14,344 psf respectively in the same period.

In Thane and Navi Mumbai area, average prices grew from Rs 1,934 psf and Rs 1,730 psf in January 2005 to Rs 9,190 psf and Rs 6,475 psf in December 2013 respectively. The strong growth trend in real estate prices was also visible beyond the MMR region i.e. suburbs beyond Thane and Borivali, which saw per square foot rates shoot from Rs 1,055 and Rs 1,063 in January 2005 to Rs 4,571 and 5,237 in December 2013 respectively.

While realty market over the years has shown a lot of potential for investments, the overall economic environment in the recent past has changed thus raising questions as to whether wealth creation still holds true in the current scenario. Industry experts feel it does. “Intelligent investment into residential property still holds the potential of significant wealth creation. However, the market keeps changing and one needs to understand these changes,” said Ahuja.

So if you are keen on taking the plunge and investing your surplus in the residential property segment, following are some of the options in the MMR, according to Jones Lang LaSalle India that can be looked into for potential investments currently.

Bandra Kurla Complex (BKC): Currently quoting at Rs 27,500 psf to Rs 50,000 psf can double in 4-5 years time. Budget range from Rs 6 crore to Rs 25 crore. Walk to work concept, lesser supply and Central Business District are the key drivers .

Chembur / Tilak Nagar: Currently quoting at Rs 12,500 psf to Rs 20,000 psf can double in 3-5 years time. Budget range from Rs 2 crore to Rs 6 crore. Monorail, lesser supply and Santacruz Link Road are the key triggers.

Mahalaxmi / Jacob Circle: Currently quoting at Rs 20,500 psf to Rs 55,000 psf can double in 4-5 years time. Budget range from Rs 9 crore to Rs 25 crore. Monorail, gated community, lesser supply, south Mumbai profile like this area for race course view, eastern freeway are key triggers.

Ghatkopar / Chandivali: Currently quoting at Rs 12,500 psf to Rs 16,000 psf can double in 5-6 years time. Budget range from Rs 2 crore to Rs 5 crore. Closer to Powai where multi-national companies have offices, closer to metro, eastern freeway to get terminated at Ghatkopar junction, value for money at current price points.

Mulund / Bhandup / Ghodbunder: Currently quoting at Rs 10,000 psf to Rs 15,000 psf can double in 5-6 years time. Budget range from Rs 1 crore to Rs 3 crore. Better social infrastructure, better road connectivity and environmentally best in Mumbai.

“As for areas like Wadala, Lower Parel, Dombivli, Malad, Goregaon etc. there is enough supply that will hit the market where percentage appreciation will become a big challenge. Infrastructure is collapsing currently and don't see visibility of any major developments in terms of public transport and social infrastructure,” cautions Ahuja.

HCL Corp forays into healthcare, launches India's first nation-wide networked multi-specialty clinics under HCL Avitas

HCL Corporation, the parent company of HCL Technologies and HCL Infosystems, has forayed into the healthcare sector with plans to be one of India's largest healthcare service providers. The new business entity, HCL Healthcare will address the entire spectrum of healthcare needs including providing healthcare delivery, innovative medical services, products and training to meet the growing need for quality healthcare.

Accordingv to Shiv Nadar, founder & chairman, HCL and Shiv Nadar Foundation, education, healthcare and technology will be the key enablers of India's future progress and growth. “Over the last 38 years, HCL has been at the forefront of technology and innovation. I have personally been committed to the cause of education through the Foundation for 20 years,” said Nadar adding that the company's entry into healthcare is an area of paramount national importance.

Kickstarting the venture, the company has launched a subsidiary called HCL Avitas in affiliation with Johns Hopkins Medicine International. Offering a of healthcare delivery offerings, HCL Avitas is positioned as India's first nation-wide networked multi-specialty clinics. The clinics will adopt global best practices for medical quality and training using evidence-based systems and integrating advanced technology to provide unmatched patient experience and outcomes.

Steven J Thompson, CEO, Johns Hopkins Medicine International, said, that HCL was a strong and trusted brand with a steadfast commitment to transform healthcare in India. “Together with HCL Avitas, we hope to establish a new paradigm in patient-centered care in India,” said Thompson.

HCL Healthcare observed that India has a shifting disease burden that is influenced by changing lifestyles and that this need is grossly underserved. “Our technology expertise and the ability to create scalable institutions will help us institute new benchmarks in healthcare delivery in India. Creating an organised technology-led health system that will be the long-term care partner is our immediate goal. HCL Healthcare intends to be that partner and provide patient-centered care for over 20 million people by 2020,” said Shikhar Malhotra, vice chairman, HCL Healthcare.

In the launch phase, HCL Avitas will establish a network of multi-specialty clinics across the country starting with the National Capital Region. Harish Natarajan, chief executive officer, HCL Avitas, said, “Technology is our strength – our clinics will all be networked giving patients access to their medical history and to the best specialists available in our system. Through our association with Johns Hopkins, we will bring in global best practices and the best evidence-based systems. In the next 5 years, we expect to have over 1500 doctors in our network across various cities in the country,” said Natarajan.

Banknotes issued prior to 2005 to be withdrawn: RBI Advisory

The Reserve Bank of India on January 22, 2014, advised that after March 31, 2014, it will completely withdraw from circulation all banknotes issued prior to 2005. 

In a note on its website, RBI said that from April 1, 2014, the public will be required to approach banks for exchanging these notes. Banks will provide exchange facility for these notes until further communication. 

The Reserve Bank further stated that public can easily identify the notes to be withdrawn as the notes issued before 2005 do not have on them the year of printing on the reverse side. (Please see illustration below)

 The Reserve Bank has also clarified that the notes issued before 2005 will continue to be legal tender. This would mean that banks are required to exchange the notes for their customers as well as for non-customers.

From July 01, 2014, however,  to exchange more than 10 pieces of Rs 500 and Rs 1,000 notes, non-customers will have to furnish proof of identity and residence to the bank branch in which she/he wants to exchange the notes.

The Reserve Bank has appealed to the public not to panic. They are requested to actively co-operate in the withdrawal process.

Ranbaxy's biggest bulk drug unit under US FDA scanner

This story first appeared in DNA Money edition on Tuesday, January 14, 2014

Troubles do not seem to end for Ranbaxy Laboratories, which saw its shares tank 9.47% on Monday after one of its key facilities at Toansa, Punjab, was slapped with Form 483 by the US Food and Drug Administration (FDA).

Form 483 is issued at the conclusion of an inspection when investigators observe any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic Act and related Acts.

The shares of Ranbaxy, the biggest Indian drugmaker by sales, opened at Rs 466 on Monday and reached a low of Rs 420 before closing the day at at Rs 438.80,  down 5.58% from the previous close.

This is the second biggest fall since September 2013 when the stock had lost 30.27% of its value following an import alert on its Mohali plant by the US FDA for violation of current good manufacturing practices.

In a note to the exchanges, Ranbaxy said, “It is assessing the observations, and will respond to the US FDA in accordance with the agency’s procedure to resolve the concerns at the earliest.”

While Ranbaxy management did not share any production related details, industry experts said the plant manufactures around 70-75% of its API requirements.

Under the Form 483 process, the company would now have to respond with its corrective action plan and implement it expeditiously or face an import alert.

Sarabjit Kour Nangra, vice-president, research-pharma, Angel Broking, said, “During the second quarter of calendar year 2013, its other key facility at Mohali came under US FDA import alert. With this plant also under scanner, it would have impact on the operations of the company in the US, unless it can compensate for the same at the earliest and mange a smooth supply of key raw materials,” said Nangra.

She said more clarity is awaited from the Ranbaxy management in order to ascertain the exact impact on the financials, especially operating profit margins.

“Until then, the company could trade at a huge discount to its peers,” said Nangra.

Getting US FDA clearance will be crucial for Ranbaxy considering all of its India-based factories are currently banned by the regulator from exporting medicines to the US, its largest market.

Last week Ranbaxy inked a licensing pact with EPIRUS Switzerland GmbH for BOW015, a biosimilar version of Infliximab, prescribed to treat rheumatoid arthritis, and said the product will be introduced in India and other emerging markets.

Ranjit Kapadia, senior vice-president - pharma, Centrum Broking, said the molecule has only completed Phase 3 studies. “It would take 12-18 months to get regulatory approval and commercialise the product in India,” he said.

Will Wockhardt turn rocket for its lone Mutual fund believer?

My colleague Nupur Anand is the lead writer of this story appearing in DNA Money edition on Monday, Janart 13, 2014.

Last time when the Wockhardt shares shot up a whopping 350% was in 2012 after the drug firm successfully came out of debt restructuring.

This time buffeted by issues with the US Food and Drug Administration, the stock is again in doldrums -- between April and December it lost 83%, down to a new low of Rs 339.85 from Rs 2,024.90 at the start of the fiscal.

And now rooting for an encore is Prashant Jain, chief investment officer of HDFC MF, India’s largest fund house, who known for taking contra calls and unusual bets that have paid off.

As Wockhardt stock nosedived, several retail investors and mutual fund houses started dumping it.

In the same period, Jain quietly picked up the pharma firm’s shares.

Till April last year, HDFC MF had zero shares of Wockhardt, whereas other mutual funds held 10.34 lakh shares.

By September end, HDFC has 13.59 lakh shares, a whooping 97% of the total shares held by mutual fund houses.

Out of the total 1.36% shares of Wockhardt held by MFs, Jain alone holds 1.29%.

Under Jain’s watch, the asset under management of HDFC MF have grown to mammoth size of Rs 108,990 crore.

And market experts believe that this contra call by Jain may pay off.

An expert with a foreign brokerage said, “The rationale behind Prashant Jain’s optimism has to do with his philosophy on finding deep value stocks which he can hold, and expect higher value to unravel when it tides through difficult times. To me, the recent stock correction factors a worst-case scenario.”

A pharma analyst from a leading domestic brokerage added, “Fundamentally, despite trouble with US FDA, the residual business would have enough earnings power to justify current price. The current balance-sheet health is much stronger than ever, and hereon there can only be upside to earnings outlook. The kind of turnaround Prashant Jain has seen in Aurobindo could be something he is betting on in case of Wockhardt, once the regulatory issues are tackled.”

Bad times for Wockhardt started in May after the USFDA put an import alert on its Waluj plant and intensified between May and November, when the company being hauled up four more times by the US and the UK drug regulators.

Sarabjit Kour Nangra, VP-research, pharma, Angel Broking also believes that Jain’s bet may pay off.

“The Wockhardt stock took significant beating last year and has probably gone through the worst times. But one needs to also take into account that the company successfully came out of the financial mess in the years before that and Jain is certainly betting on its revival from the US FDA and UK Medicines and Healthcare Products Regulatory Agency issues,” said Nangra.

“One also needs to remember that Wockhardt is one of the biggest players in the pharma industry and investors with a long-term view would certainly take exposure as the risk-reward is huge,” she said.

Wockhardt stock has been recovering slowly and is now trading at Rs 424.95, already up 25% from the December low of Rs 339.85.

Wockhardt’s foreign drug regulator alerts

May 2013 - US Food and Drug Administration import alert on Waluj Plant

July - UK Medicines and Healthcare Products Regulatory Agency (UK MHRA) import alert on Waluj plant

Oct - UK MHRA withdraws Good Manufacturing Practice (GMP) certificate for Daman plant

Oct - UK MHRA withdraws GMP for Chikalthana plant

Nov - US FDA import alert on Chikalthana plant

Dec - US FDA import alert on Chikalthana and Waluj units for veterinary drugs

Now, IHCL aligns its United Kingdom hotels with Taj brand

This story first appeared in DNA Money edition on Wednesday, January 08, 2014.

Indian Hotels (IHCL), Tata’s hospitality business vertical, has rebranded two of its hotels in the United Kingdom (UK), aligning them with its luxury positioning in the international hospitality market.

The UK hotels will now be promoted within the Taj group’s portfolio of luxury hotels, resorts and palaces.

Taj management said it now has sole ownership and management, as well as operational and marketing control, of both properties.

The over a century old Crowne Plaza London - St James, a property located in central London and featuring 340 guestrooms and 21 suites, has been renamed St James’s Court, a Taj Hotel. While the published rate for a standard room at this hotel is £495 (around Rs 50,500) for a night’s stay, the best available rate as shown on its website is £119 (Rs 12,100) including the value-added tax or VAT.

Similarly, 51 Buckingham Gate, Taj Suites & Residences (pictured, below; 86 luxury suites and residences) has been re-branded Taj 51 Buckingham Gate Suites and Residences. With a published rate of £720 for a base category room, the hotel’s website shows £360 and £324 as best available and early bird (non-refundable) rates for a night’s stay.

Raymond Bickson, MD and CEO of the Taj group, said that the rebranding comes at an exciting time for the increasing strategic links between India and the UK. “We are delighted to have the opportunity to restore these iconic hotels that have more than a century of heritage.”

Deepa Harris, senior VP-global sales and marketing, the Taj Group, said that the success of the two London hotels has provided impetus to consolidate Taj’s brand presence in the UK, an important source market where the Tata group has had a presence for over a century, and is now the UK’s largest manufacturing sector employer and one of its largest foreign investors.

Both hotels have undergone phased renovations at considerable (but undisclosed) investment from the Taj group.

Taj will add to the Tata brands portfolio in the UK that includes Jaguar, Land Rover, Tata Steel Europe (formerly Corus) and Tetley Tea.